MDT Stock Analysis: Medtronic | NYSE
Medical Devices | NYSE, USA | Market Cap: 110.569m USD | 12M Return: -5.3% | IE00BTN1Y115 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 1.62B
EPS Trend: 87.4%
Qual. Beats: 1
Rev. Trend: 96.4%
Qual. Beats: 5
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Medtronic plc is a global medical device company that develops, manufactures, and distributes device-based medical therapies across three main segments: Cardiovascular, Neuroscience, and Medical Surgical. The company sells to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and international markets. Its Cardiovascular Portfolio includes pacemakers, defibrillators, cardiac ablation products, heart valves, and stent grafts. The Neuroscience Portfolio covers spinal and brain stimulation systems, drug infusion devices, and nerve ablation products for specialists including neurosurgeons, pain management, and orthopedic surgeons. The Medical Surgical Portfolio offers surgical stapling and sealing devices, robotic-assisted surgery products, hernia and gynecology products, patient monitoring systems, and insulin pumps with continuous glucose monitoring supplies.
The company is headquartered in Ireland and listed on the NYSE under the ticker MDT, classified within the Health Care Equipment sub-industry. As a diversified medical device manufacturer, Medtronic operates a broad portfolio model spanning multiple therapeutic areas, which is typical of large-cap medtech companies seeking to reduce reliance on any single product line.
- Diabetes unit divestiture to MannKind reshapes Medical Surgical margins
- Hugo robotic-assisted surgery gains traction against Intuitive Surgicals da Vinci platform
- Cardiovascular segment faces TAVR pricing pressure from Edwards Lifesciences competition
| Net Income: 5.23b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.74 > 1.0 |
| NWC/Revenue: 33.54% < 20% (prev 34.19%; Δ -0.65% < -1%) |
| CFO/TA 0.09 > 3% & CFO 8.04b > Net Income 5.23b |
| Net Debt (19.4b) to EBITDA (10.3b): 1.89 < 3 |
| Current Ratio: 2.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago -0.16% < -2% |
| Gross Margin: 66.69% > 18% (prev 63.44%; Δ 3.25% > 0.5%) |
| Asset Turnover: 40.74% > 50% (prev 37.59%; Δ 3.15% > 0%) |
| Interest Coverage Ratio: 10.11 > 6 (EBIT TTM 7.33b / Interest Expense TTM 725.0m) |
| A: 0.13 (Total Current Assets 24.4b - Total Current Liabilities 11.8b) / Total Assets 93.3b |
| B: 0.36 (Retained Earnings 33.2b / Total Assets 93.3b) |
| C: 0.08 (EBIT TTM 7.33b / Avg Total Assets 92.1b) |
| D: 1.18 (Book Value of Equity 50.2b / Total Liabilities 42.5b) |
| Altman-Z'' = 3.82 = AA |
| DSRI: 0.10 (Receivables 224.0m/6.26b, Revenue 37.5b/34.2b) |
| GMI: 0.95 (GM 63.44% / 66.69%) |
| AQI: 0.99 (AQ_t 0.66 / AQ_t-1 0.67) |
| SGI: 1.10 (Revenue 37.5b / 34.2b) |
| TATA: -0.03 (NI 5.23b - CFO 8.04b) / TA 93.3b) |
| Beneish M = -3.75 (Cap -4..+1) = AAA |
As of October 10, 2026, the stock is trading at USD 88.48 with a total of 38,860,319 shares traded. Over the past week, the price has changed by +2.43%, over one month by -2.92%, over three months by +8.27% and over the past year by -5.27%.
Current recommended Stop Loss: 83.60 (which is 5.5% or 2.2 ATR below the current price).
Medtronic has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy MDT.
- StrongBuy: 16
- Buy: 3
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 104.8 | 18.5% |
P/E Trailing = 21.2383
P/E Forward = 14.9254
P/S = 2.9452
P/B = 2.274
P/EG = 1.6044
Revenue TTM = 37.5b USD
EBIT TTM = 7.33b USD
EBITDA TTM = 10.3b USD
Long Term Debt = 25.6b USD (from longTermDebt, last quarter)
Short Term Debt = 2.54b USD (from shortTermDebt, last quarter)
Debt = 28.2b USD (from shortLongTermDebtTotal, last quarter) + Leases 52.0m
Net Debt = 19.4b USD (calculated: Debt 28.2b - CCE 8.82b)
Enterprise Value = 130b USD (111b + Debt 28.2b - CCE 8.82b)
Interest Coverage Ratio = 10.11 (Ebit TTM 7.33b / Interest Expense TTM 725.0m)
EV/FCF = 21.19x (Enterprise Value 130b / FCF TTM 6.13b)
FCF Yield = 4.72% (FCF TTM 6.13b / Enterprise Value 130b)
FCF Margin = 16.33% (FCF TTM 6.13b / Revenue TTM 37.5b)
Net Margin = 13.93% (Net Income TTM 5.23b / Revenue TTM 37.5b)
Gross Margin = 66.69% ((Revenue TTM 37.5b - Cost of Revenue TTM 12.5b) / Revenue TTM)
Gross Margin QoQ = 64.99% (prev 75.86%)
Tobins Q-Ratio = 1.39 (Enterprise Value 130b / Total Assets 93.3b)
Interest Expense / Debt = 2.57% (Interest Expense 725.0m / Debt 28.2b)
Taxrate = 20.19% (1.33b / 6.60b)
NOPAT = 5.85b (EBIT 7.33b * (1 - 20.19%))
Current Ratio = 2.07 (Total Current Assets 24.4b / Total Current Liabilities 11.8b)
Debt / Equity = 0.56 (Debt 28.2b / totalStockholderEquity, last quarter 50.2b)
Debt / EBITDA = 1.89 (Net Debt 19.4b / EBITDA 10.3b)
Debt / FCF = 3.16 (Net Debt 19.4b / FCF TTM 6.13b)
Total Stockholder Equity = 49.3b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.68% (Net Income 5.23b / Total Assets 93.3b)
RoE = 10.60% (Net Income TTM 5.23b / Total Stockholder Equity 49.3b)
RoCE = 9.79% (EBIT 7.33b / Capital Employed (Equity 49.3b + L.T.Debt 25.6b))
RoIC = 7.12% (NOPAT 5.85b / Invested Capital 82.2b)
WACC = 5.32% (E(111b)/V(139b) * Re(6.15%) + D(28.2b)/V(139b) * Rd(2.57%) * (1-Tc(0.20)))
Discount Rate = 6.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -62.02 | Cagr: -1.36%
[DCF] Terminal Value 77.97% ; FCFF base≈5.80b ; Y1≈6.65b ; Y5≈9.79b
[DCF] Fair Price = 99.97 (EV 147b - Net Debt 19.4b = Equity 128b / Shares 1.28b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 87.41 | EPS CAGR: 3.12% | SUE: 4.0 | # QB: 1
Revenue Correlation: 96.38 | Revenue CAGR: 5.63% | SUE: 2.26 | # QB: 5
EPS current Quarter (2026-10-31): EPS=1.33 | Chg30d=-1.17% | Revisions=-53% | Analysts=23
EPS next Quarter (2027-01-31): EPS=1.42 | Chg30d=-0.56% | Revisions=-56% | Analysts=23
EPS current Year (2027-04-30): EPS=5.97 | Chg30d=+0.43% | Revisions=+71% | GrowthEPS=+8.0% | GrowthRev=+7.5%
EPS next Year (2028-04-30): EPS=6.41 | Chg30d=+0.10% | Revisions=-16% | GrowthEPS=+7.3% | GrowthRev=+3.4%
[Analyst] Revisions Ratio: -8% (up=33, down=39)